A Phase Ib Study Of Cobimetinib Administered In Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-Sensitive Ovarian Cancer


About this study

This is a Phase Ib, open-label, randomized, multicenter, two-arm study designed to assess the safety, efficacy, and pharmacokinetics of cobimetinib administered in combination with niraparib, with or without atezolizumab, to patients with advanced platinum-sensitive ovarian cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Hypertension (TAs > 130, TAd > 80mmHg or under antihypertensive treatment).
  • Glomerular nephropathy, proteinuria > 1 g/day, serum creatinin < 200 µmol/L.
  • Informed consent given.
  • No contraindication for ARB and hydrochlorothiazide.
  • Efficient contraception for women.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Gerardo Colon-Otero, M.D.

Closed for enrollment

Contact information:

Gerardo Colon-Otero M.D.



More information


Publications are currently not available

Mayo Clinic Footer